ABSTRACT
Neuroprotective properties of the new derivative of glutamic and apovincaminic acids, ethyl -(3-alpha,16-alpha)-eburnamenin-14-carbopxylate of 2-aminopentadionic acid (LHT 1-02) were studied on a model of acute brain ischemia in cats. LHT 1-02 has proved to be more effective than the reference drugs vinpocetin and glycine in preventing the reperfusive damage, which was manifested by decreased postischemic hyperglycemia, activated utilization of oxygen in the brain, and suppressed postischemic metabolic lactate acidosis. Thus, the results of this comparative study show expediency of further investigations of LHT 1 - 02 as a potential neuroprotective drug.
Subject(s)
Brain Ischemia/drug therapy , Brain/drug effects , Glutamic Acid/pharmacology , Neuroprotective Agents/pharmacology , Reperfusion Injury/drug therapy , Vinca Alkaloids/pharmacology , Acidosis, Lactic/prevention & control , Animals , Blood Glucose/metabolism , Brain/metabolism , Brain Ischemia/metabolism , Cats , Glutamic Acid/analogs & derivatives , Glutamic Acid/chemical synthesis , Glycine/pharmacology , Lactic Acid/antagonists & inhibitors , Lactic Acid/biosynthesis , Neuroprotective Agents/chemical synthesis , Oxygen Consumption/drug effects , Reperfusion Injury/metabolism , Vinca Alkaloids/chemistryABSTRACT
Neuroprotector properties of a new apovincaminic acid derivative (LHT 2 - 02) were studied on a model of acute brain ischemia in cats. LHT 2 - 02 has proved to be more effective than the reference drugs vinpocetin and glycine in preventing the reperfusive damage, which was manifested by decreased postishemic hyperglycemia and suppressed postishemic metabolic lactate acidosis.
